<PAGE> 1
As filed with the Securities and Exchange Commission on October 2, 1998
REGISTRATION NO. 333-58849
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
AMENDMENT NO. 2
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
-----------------
LIFEQUEST MEDICAL, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 74-2559866
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
12961 PARK CENTRAL, SUITE 1300
SAN ANTONIO, TEXAS 78216
(210) 495-8787
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
-----------------
RANDALL K. BOATRIGHT
EXECUTIVE VICE PRESIDENT,
CHIEF FINANCIAL OFFICER AND SECRETARY
LIFEQUEST MEDICAL, INC.
12961 PARK CENTRAL, SUITE 1300
SAN ANTONIO, TEXAS 78216
(210) 495-8787
(Name, address, including zip code and telephone number,
including area code, of agent for service)
---------------
Copy to:
PHILLIP M. RENFRO
FULBRIGHT & JAWORSKI L.L.P.
300 CONVENT STREET, SUITE 2200
SAN ANTONIO, TEXAS 78205
(210) 224-5575
-----------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: From
time to time after this Registration Statement becomes effective. If the only
securities being registered on this Form are being offered pursuant to dividend
or interest reinvestment plans, please check the following box. [ ]
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with
dividend or interest reinvestment plans, check the following box. [x]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ] __
If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ] __
If delivery of the prospectus is expected to be made pursuant to Rule
434, please check the following box. [ ]
---------------------------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE
OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
===============================================================================
<PAGE> 2
P R O S P E C T U S
370,000 SHARES
LIFEQUEST MEDICAL, INC.
COMMON STOCK
---------------
This Prospectus has been prepared for use in connection with the
proposed sale or distribution by certain stockholders (the "Selling
Stockholders") of an aggregate of 370,000 shares (the "Shares") of common
stock, par value $.001 per share ("Common Stock"), of LifeQuest Medical, Inc.
(the "Company"). The Shares may be sold from time to time by or for the account
of the Selling Stockholders in the over-the-counter market, on the National
Association of Securities Dealers Automated Quotation System, Inc. ("NASDAQ")
or otherwise at prices and on terms then prevailing or at prices related to the
then current market price, or in negotiated transactions. The Shares may be
sold by any one or more of the following methods: (a) a block trade in which
the broker or dealer so engaged will attempt to sell the securities as agent
but may position and resell a portion of the block as principal to facilitate
the transaction; (b) purchases by a broker or dealer as principal and resale by
such broker or dealer for its account pursuant to this Prospectus; (c) ordinary
brokerage transactions and transactions in which the broker solicits
purchasers; and (d) privately negotiated transactions.
The Common Stock is traded on the NASDAQ SmallCap Market System (the
"SmallCap Market") under the symbol "LQMD." On October 1, 1998, the last
reported sale price for the Common Stock on the SmallCap Market was $1.375 per
share.
The Company will receive no portion of the proceeds of the sale of the
Shares offered hereby and will bear all costs and expenses incident to their
registration. See "Plan of Distribution."
The Shares have not been registered for sale under the securities laws
of any state or jurisdiction as of the date of this Prospectus. Brokers or
dealers effecting transactions in the Shares should confirm the registration
thereof under the securities laws of the states in which such transactions
occur, or the existence of any exemption from registration.
---------------
PROSPECTIVE INVESTORS SHOULD CAREFULLY CONSIDER THE MATTERS SET
FORTH UNDER THE CAPTION "RISK FACTORS."
---------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECU-
RITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this Prospectus is October 2, 1998
<PAGE> 3
AVAILABLE INFORMATION
The Company has filed with the Securities and Exchange Commission (the
"SEC") in Washington, D.C., a Registration Statement on Form S-3 (the
"Registration Statement") under the Securities Act of 1933, as amended (the
"Securities Act"), with respect to the securities offered by this Prospectus.
Certain of the information contained in the Registration Statement is omitted
from this Prospectus, and reference is hereby made to the Registration
Statement and exhibits and schedules relating thereto for further information
with respect to the Company and the securities offered by this Prospectus. The
Company is subject to the informational requirements of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), and, in accordance therewith,
files reports, proxy statements and other information with the SEC. Such
reports, proxy statements and other information are available for inspection
and copies of such materials may be obtained upon payment of the fees
prescribed therefor by the rules and regulations of the SEC from the SEC, at
its principal offices located at Judiciary Plaza, 450 Fifth Street, Room 1024,
Washington, D.C. 20549, and at the following regional offices of the SEC:
Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois
60661-2511 and at Seven World Trade Center, Suite 1300, New York, New York
10048, and copies of all or any part of the Registration Statement may be
obtained from the Public Reference Section of the SEC, at 450 Fifth Street,
N.W., Judiciary Plaza, Washington, D.C. 20549 upon the payment of the fees
prescribed by the SEC. The SEC maintains a WorldWide Web site on the Internet
at http://www.sec.gov that contains reports, proxy statements and other
information regarding registrants that file electronically with the SEC.
INCORPORATION OF CERTAIN DOCUMENTS
The Company's Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1997, the Company's Quarterly Reports on Form 10-QSB for the
quarters ended March 31 and June 30, 1998, respectively, and the Company's
Current Report on Form 8-K dated July 1, 1998 are hereby incorporated herein by
reference.
The description of the Company's Common Stock, which is contained under
the caption "Description of Capital Stock" in the Registration Statement on
Form S-1 dated August 19, 1992 (Registration No. 33-49196), as post-effectively
amended by the Registration Statement on Form S-1 dated August 20, 1992
(Registration No. 33-51046), and the description of the Company's Common Stock
Purchase Rights set forth in the Registration Statement on Form 8-A dated June
20, 1995, are hereby incorporated herein by reference.
All documents filed by the Company pursuant to Section 13(a), 13(c), 14
or 15(d) of the Exchange Act, after the date of this Prospectus and prior to
the termination of the Registration Statement of which this Prospectus is a
part with respect to registration of the Shares, shall be deemed to be
incorporated by reference in this Prospectus and be a part hereof from the date
of filing of such documents. Any statement contained in a document incorporated
or deemed to be incorporated by reference in this Prospectus shall be deemed to
be modified or superseded for purposes of this Prospectus to the extent that a
statement contained in this Prospectus, or in any other subsequently filed
document which also is or is deemed to be incorporated by reference, modifies
or replaces such statement.
The Company undertakes to provide without charge to each person to whom
a copy of this Prospectus has been delivered, upon written or oral request of
any such person, a copy of any or all of the documents incorporated by
reference herein, other than exhibits to such documents, unless such exhibits
are specifically incorporated by reference into the information that this
Prospectus incorporates. Written or oral requests for such copies should be
directed to: LifeQuest Medical, Inc., 12961 Park Central, Suite 1300, San
Antonio, Texas 78216, Attention: Randall K.
Boatright, telephone (210) 495-8787.
-2-
<PAGE> 4
THE COMPANY
LifeQuest Medical, Inc., a Delaware corporation (the "Company"), and
its subsidiary, ValQuest Medical, Inc., a Nevada corporation ("ValQuest"), are
primarily engaged in the development, manufacture and distribution of
instruments, equipment and surgical supplies used in minimally invasive surgery
("MIS"). A glossary of technical terms used herein can be found on page 15 of
this Prospectus.
Minimally invasive surgery, a rapidly growing field, involves surgical
procedures, accomplished without a major incision, through strategically placed
punctures in a patient's body. These procedures generally result in reduced
patient discomfort, reduced risks of infection and greatly shortened
hospitalization, thereby decreasing overall costs. MIS products include a wide
variety of reusable and disposable items such as endoscopes, trocars, trocar
sleeves/cannulas, video systems, mechanical and laser-related cutting devices,
stapling systems, electrocautery systems, suction and irrigation systems,
graspers and dissectors and hand-operated retractors. The products are used by
surgeons in hospitals and outpatient surgery facilities.
In June 1998, the Company acquired approximately 4% of the membership
interests of Ana-Tech, L.L.C., a developmental stage company engaged in the
development, manufacturing and distribution of fecal incontinence devices.
Ana-Tech, LLC is a Nevada limited liability company and has one class of
membership interests. As a member of Ana-Tech, the Company has the right, along
with the other members, to participate in elections of managers of Ana-Tech,
LLC and to receive distributions of Net Cash Flow and Net Capital Proceeds
(each as defined in the Operating Agreement of Ana-Tech, LLC) on a pro-rata
basis in accordance with the Company's percentage of ownership of Ana-Tech,
LLC. Allocations of profit and loss of Ana-Tech, LLC will be allocated among
the members of Ana-Tech, LLC pro-rata in accordance with percentage of
ownership.
In January 1998, the Company acquired approximately 20% of the voting
common stock of TFX Holding Co. ("TFX"), a business development subsidiary of
Teleflex, Inc. TFX owns the Dexterity(R) Pneumo Sleeve and the Dexterity(R)
Protractor, which the Company distributes pursuant to a distribution agreement
with TFX.
The Pneumo Sleeve is a device which allows the surgeon to insert one
hand into the abdominal cavity while preserving pneumoperitoneum during
laparoscopic surgery. This new surgical modality, called Hand Assisted
Laparoscopic Surgery (HALS), is a hybrid between open and laparoscopic surgery.
This enabling technology is expected to greatly increase the number of advanced
minimal access surgeries as well as the number of surgeons who perform these
procedures.
In addition to being used with the Dexterity(R) Pneumo Sleeve, the
Dexterity(R) Protractor is used as a stand-alone product for open surgery,
providing atraumatic retraction and wound protection.
The Company acquired Mishbucha, Inc. d/b/a Medex Surgical, a Texas
corporation ("Medex"), effective September 1997. Medex is located in Dallas,
Texas, and distributes instruments, equipment and surgical supplies used
in MIS.
The Company acquired W.H. Bookwalter and Associates, Inc., a Vermont
corporation ("Bookwalter"), effective September 1997. Bookwalter is located in
Milford, Massachusetts, and develops, manufactures and distributes equipment,
instruments and surgical supplies used in MIS.
Effective June 1997, the Company acquired Trimedica, Inc., a Colorado
corporation located in Colorado Springs, Colorado, which distributes
instruments, equipment and surgical supplies used in MIS.
The Company acquired Klein Medical, Inc., a Texas corporation
("Klein"), in November 1996 and Val-U-Med, Inc., a Georgia corporation
("Val-U-Med"), in December 1996, private companies located in San Antonio,
Texas and Atlanta, Georgia, respectively. Both companies, which became wholly
owned subsidiaries of the Company, distribute instruments, equipment and
surgical supplies used in MIS.
-3-
<PAGE> 5
In February 1996, the Company completed the merger of GM Engineering,
Inc., a California corporation ("GM Engineering"), with and into LifeQuest
Endoscopic Technologies, a wholly owned subsidiary of the Company ("LQET").
In May 1994, the Company and Valdor Fiber Optics of San Jose,
California, formed a corporate venture, ValQuest, which is an 82% owned
subsidiary of the Company. ValQuest's patented Impact Mount(TM) technology is
being used to develop proprietary, autoclavable (heat sterilizable), flexible,
fiber optic endoscopes which are expected to have applications in the MIS
field.
The Company intends to continue to allocate its resources toward
becoming a more significant competitor in the MIS market by utilizing the
combined capabilities of its subsidiaries to expand its geographical
distribution coverage in the U.S. and add relevant new products to its existing
line through internal development, licensing and acquisition.
The Company was incorporated on December 23, 1988 as a Delaware
corporation and commenced operations on January 1, 1989. In August 1992, the
Company completed its initial public offering of Common Stock which is quoted
on the NASDAQ SmallCap Market. Effective January 1, 1998, the Company merged
each of its wholly-owned subsidiaries, LQET, Klein and Val-U-Med, into the
Company. The Company's executive offices are located at 12961 Park Central,
Suite 1300, San Antonio, Texas 78216, and its telephone number is (210)
495-8787.
RISK FACTORS
An investment in the Common Stock offered hereby involves a high degree
of risk. Prospective investors should consider carefully the following risk
factors, as well as the other information set forth in this Prospectus, in
connection with an investment in the Common Stock offered hereby. Other than
historical and factual statements, the matters and items discussed in this
Prospectus are forward-looking statements that involve risks and uncertainties.
The Company's actual results may differ materially from the results discussed
in the forward-looking statements. In addition to other information contained
in this Prospectus, the following factors could contribute to such differences.
Prospective investors should carefully consider the following factors and
cautionary statements in determining whether to purchase shares of Common Stock
in the offering made hereby. All factors should be considered in conjunction
with the other information and financial data appearing elsewhere in this
Prospectus and in the documents incorporated herein by reference. See
"Disclosure Regarding Forward-Looking Statements."
HISTORY OF LOSSES; PROFITABILITY UNCERTAIN. The Company has experienced
operating losses since its inception on January 1, 1989. For the quarters ended
March 31 and June 30, 1998, the Company had a net loss of approximately
$625,000 and $112,000, respectively. For the years ended December 31, 1996 and
1997, the Company had a net loss of approximately $2,000,000 and $3,000,000,
respectively. At June 30, 1998, the Company had an accumulated deficit of
approximately $18.1 million. Prior to the acquisitions of GM Engineering, Klein
and Val-U-Med, the Company was a development stage company focused primarily on
obtaining FDA approval of two medical devices. However, the Company has
determined not to initiate any further work on obtaining FDA approval of the
devices unless an appropriate corporate partner can be identified. Primarily as
a result of its acquisitions in 1996 and 1997, the Company generated revenues
of approximately $14.3 million during the year ended December 31, 1997.
In the future, the Company expects to have increased cash outflow
requirements as a result of expenditures related to the expansion of sales and
marketing activity, expansion of manufacturing capacity, compliance with
regulatory requirements, and possible investment in or acquisition of
additional complementary products, technologies or businesses. The cash needs
of the Company have changed significantly as a result of the acquisitions
completed during the last two years and the support requirements of the added
business focus areas. There can be no assurance that the Company will not
continue to incur losses, that the Company will be able to raise cash as
necessary to fund operations or that the Company will ever achieve
profitability.
RECENT PRIVATE PLACEMENT OF PREFERRED STOCK; SUPERIOR RIGHTS OF HOLDERS
OF SERIES A PREFERRED STOCK. In August 1998, pursuant to the terms of a private
placement, the Company issued to two affiliates of Renaissance Capital Group,
Inc. (collectively, such affiliates referred to herein as "Renaissance") and
two individuals, including one who is an officer and director of the Company,
an aggregate of 1,170 shares of 8% Series A Cumulative Preferred Stock,
-4-
<PAGE> 6
$.001 par value ("Series A Preferred Stock), for aggregate proceeds of
$1,170,000. On the date the Company closed such private placement, August 11,
1998, the closing per share price of Common Stock on the NASDAQ SmallCap Market
was $1.75. The Company intends to use such proceeds for working capital. Annual
dividends on the Series A Preferred Stock are cumulative at a rate of $80 per
share. The Series A Preferred Stock is initially convertible into shares of
Common Stock at a conversion price of $2 per share, for an aggregate of 585,000
shares of Common Stock; however, since the conversion price is subject to
downward adjustment as described below, and there is no minimum conversion
price, the maximum number of shares of Common Stock which may be issued
pursuant to the conversion of the preferred stock is undeterminable. Such
uncertainty creates downward pressure on the public market price of the Common
Stock. The conversion price for the Series A Preferred Stock is subject to
downward adjustment in the event the Company sells shares of Common Stock, or
securities convertible into shares of Common Stock, at a per share price less
than $2. The conversion price for the Series A Preferred Stock is also subject
to a one-time downward adjustment in the event (i) the Company does not have
pre-tax income, excluding extraordinary gains, of at least $4,400,000 in 1998
and (ii) the volume-weighted average closing bid price of the Common Stock, as
determined by Bloomberg Financial Markets and Commodities News, for the
twenty-one consecutive trading days following the Company's public release of
its 1998 financial results (the "1998 Conversion Price Adjustment"), is less
than $2 per share. Upon the occurrence of (i) and (ii) above, the conversion
price of the Series A Preferred Stock will be adjusted downward to an amount
equal to the 1998 Conversion Price Adjustment. The provisions of the Company's
Certificate of Incorporation provide that the holders of the Series A Preferred
Stock have an option to redeem the Series A Preferred Stock at a redemption
price per share equal to par. The holders of Series A Preferred Stock are
entitled to one vote per share on all matters submitted to a vote of the
stockholders of the Company, and the affirmative vote of the holders of 662/3%
of the votes entitled to be cast by the holders of the Series A Preferred Stock
is required in order to amend the Company's Certificate of Incorporation or
Bylaws to materially affect the rights of the holders of Series A Preferred
Stock, including authorizing and creating a class of stock having rights prior
to or senior to the Series A Preferred Stock. In the event two quarterly
dividends payable on the Series A Preferred Stock are in arrears, the holders
of Series A Preferred Stock, by a majority vote, shall be entitled to designate
two additional directors to serve on the Company's Board of Directors.
RECENT PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES; RESTRICTIVE
FINANCIAL COVENANTS. In December 1997, the Company sold 250,000 shares of
Common Stock to Renaissance in a private placement for aggregate proceeds of
$1,000,000 and placed $3,000,000 in 9 % Convertible Debentures (the
"Debentures") with Renaissance. The proceeds from the private placement were
used to repay the Company's line of credit with another financial institution,
to make an equity investment in TFX, and for working capital purposes. The
Debentures are secured by substantially all of the assets of the Company and
require monthly payments of interest beginning in February 1998 and, unless
sooner paid, redeemed or converted, require monthly principal payments
commencing in December 2000 of $10 per $1000 of the then remaining principal
amount. The remaining principal balance will mature in December 2004. The
Debentures require the Company to comply with the following financial covenants
(all as defined in the Debentures): (i) a Debt to Net Worth Ratio of no greater
than .85:1; (ii) an Interest Coverage Ratio of at least 5:1; (iii) a Debt
Coverage Ratio of at least .10:1; and (iv) a Current Ratio of at least 1.8:1.
The Company is currently not in compliance with and has obtained a waiver from
Renaissance to suspend the Interest Coverage Ratio and Debt Coverage Ratio
covenants through December 31, 1998. The holders of the Debentures have the
option to convert at any time all or a portion of the Debentures into shares of
Common Stock at an initial price of $4 per share of Common Stock. On the date
the Company closed such private placement, December 19, 1997, the closing per
share price of the Company's Common Stock on the NASDAQ SmallCap Market was
$4.063. The conversion price is subject to downward revision if the Company
sells shares of its Common Stock, or securities convertible into Common Stock,
at a price less than $4 per share of Common Stock, subject to certain allowed
exceptions, during the term of the Debentures. Accordingly, the conversion
price for the Debentures was reduced to $2 per share of Common Stock in
connection with the August 1998 private placement. The Debentures are also
subject to a one-time adjustment to the conversion price whereby the price will
be reduced if (i) the Company does not have pre-tax income, excluding
extraordinary gains, of at least $4,400,000 in 1998 (ii) the volume-weighted
average closing bid price of the Common Stock, as determined by Bloomberg
Financial Markets and Commodities News, for the twenty-one consecutive trading
days following the Company's public release of its 1998 financial results (the
"1998 Conversion Price Adjustment"), is less than $2 per share. Upon the
occurrence of (i) and (ii) above, the conversion price of the Debentures will
be adjusted downward to an amount equal to the 1998 Conversion Price
Adjustment. The Debentures are currently convertible for an aggregate of
1,500,000 shares of Common Stock; however, since the conversion price is
subject to downward adjustment as described above, and there is no minimum
conversion price, the maximum number of shares of Common Stock which
-5-
<PAGE> 7
may be issued pursuant to conversion of the Debentures is undeterminable. Such
uncertainty creates downward pressure on the public market price of the Common
Stock. The provisions of the Debentures provide that the holders of the
Debentures have an option to redeem the Debentures, in an amount equal to an 18
percent annual yield on the principal balance, upon the occurrence of certain
events, including the delisting of Common Stock from the NASDAQ SmallCap Market
and certain "change of control" provisions, as defined in the Debentures, as
they relate to the Company. The Company may redeem the Debentures at its option
subject to certain share price and market activity levels being obtained. The
Company's right of redemption is subject to the holder's prior right of
conversion of the Debenture.
POTENTIAL ADVERSE EFFECTS OF CONVERSION OF DEBENTURES AND SERIES A
PREFERRED STOCK. The Company cannot predict what effect, if any, the conversion
of the Debentures or Series A Preferred Stock into Common Stock and/or the sale
of such Common Stock into the public market will have on the market price of
the Company's Common Stock. Offers or sales of significant quantities of the
Company's Common Stock, or the perception that such sales may occur or have
occurred, could adversely affect the market price. The conversion features of
the Debentures and Series A Preferred Stock operates such that the holders
thereof receive more shares of the Common Stock upon conversion if the
conversion price is adjusted downward as described above. The issuance of
shares of Common Stock upon the conversion of the Series A Preferred Stock or
the Debentures will dilute the voting rights and other interests of
stockholders of the Company. As the number of shares of Common Stock issuable
upon the conversion of the Series A. Preferred Stock and the Debentures is
indeterminate, the Company is unable to predict to what extent the Company's
stockholders' rights will be diluted. Such uncertainty creates downward
pressure on the public market price of the Company's Common Stock. In the event
such holders convert their Debentures or shares of Series A Preferred Stock, as
applicable, and sell a large number of shares of Common Stock into the public
market over a short time, the market price for the Common Stock could decline.
Such a decline may make future equity financings more difficult for the Company
to obtain on an acceptable basis, if at all.
In the event the conversion price for the Debentures and the Series A
Preferred Stock is adjusted downward to $1.85, the aggregate number of shares
issuable upon conversion of the Debentures and the Preferred Stock is
2,254,054. In the event the conversion price for the Debentures and the Series
A Preferred Stock is adjusted downward to $1.70, the aggregate number of shares
issuable upon conversion of the Debentures and the Preferred Stock is
2,452,941. In the event the conversion price for the Debentures and the Series
A Preferred Stock is adjusted downward to $1.50, the aggregate number of shares
issuable upon conversion of the Debentures and the Preferred Stock is
2,780,000. In the event the conversion price for the Debentures and the Series
A Preferred Stock is adjusted downward to $1.25, the aggregate number of shares
issuable upon conversion of the Debentures and the Preferred Stock is
3,336,000. In the event the conversion price for the Debentures and the Series
A Preferred Stock is adjusted downward to $1.00, the aggregate number of shares
issuable upon conversion of the Debentures and the Preferred Stock is
4,170,000.
FUTURE ADDITIONAL CAPITAL REQUIREMENTS; NO ASSURANCE FUTURE CAPITAL
WILL BE AVAILABLE. The Company's capital requirements will depend on numerous
factors, including market acceptance and demand for its products; the resources
the Company devotes to the development, manufacture and marketing of its
products; the resources required to protect the Company's intellectual
property; the resources expended, if any, to acquire complementary businesses,
products and technologies; and other factors. The timing and amount of such
capital requirements cannot be accurately predicted. Funds may also be used for
the acquisition of businesses, products and technologies that are complementary
to those marketed by the Company. Consequently, although the Company believes
that its revenues and other sources of liquidity will provide adequate funding
for its capital requirements through at least 1998, the Company may be required
to raise additional funds through public or private financings, collaborative
relationships or other arrangements. There can be no assurance that the Company
will not require additional funding or that such additional funding, if needed,
will be available on terms attractive to the Company or at all. In the event
that substantial amounts of additional financing are required, including
amounts that may be required for any potential redemption of the Debentures
described above, the Company does not believe it will be able to obtain such
financing from traditional commercial lenders. Rather, the Company likely will
have to conduct additional sales of its equity and/or debt securities. In two
private placements since December 1997, the Company has issued securities
currently convertible, at a conversion price of $2.00 per share, into 2,085,000
shares of Common Stock. If the holders of such securities were to convert them
into shares of Common Stock and sell a large number of shares of Common Stock
on the public market, the market price for the Common Stock could decline, thus
making additional equity financings more difficult
-6-
<PAGE> 8
for the Company to obtain on an acceptable basis, if at all. There can be no
assurance that such additional financing will be available if and when, and in
the amounts required, by the Company. Moreover, even if such financing is
available if and when required, there can be no assurance that such financing
will be obtained on terms that are favorable to the Company, and substantial
and immediate dilution to existing stockholders likely would result from any
sales of equity securities or other securities convertible into equity
securities. Any additional debt financings, if available, may involve
restrictive covenants.
LIMITED SALES, MARKETING AND DISTRIBUTION EXPERIENCE. The Company began
commercial sales of its first MIS products in the first quarter of 1996
following the acquisition of GM Engineering, and therefore has limited sales,
marketing and distribution experience. The Company is marketing its MIS
products as well as the MIS products of other manufacturers to hospitals and
surgeons throughout the United States. The Company markets MIS products
primarily through direct representatives who are employed by the Company within
selected geographical areas and independent sales representatives who typically
sell other complementary MIS products to the same customer base. If the need
arises, the Company may expand its sales force, which will require recruiting
and training additional personnel. There can be no assurance that the Company
will be able to recruit and train such additional personnel in a timely
fashion. Loss of a significant number of the Company's current sales personnel
or independent sales representatives, or failure to attract additional
personnel, could have a material adverse effect on the Company's business,
financial condition and results of operations.
ACQUISITION INTEGRATION. The Company's growth in recent years has
resulted from acquisitions, which involve certain operational and financial
risks. This growth has resulted in a significant increase in responsibility for
existing management which has placed, and may continue to place, a significant
strain on the Company's limited personnel and management, manufacturing and
other resources. The integration of these acquisitions has required a
significant expansion, and in some instances the replacement, of the Company's
accounting and other internal management systems and the implementation of a
variety of procedures and controls, including systems and procedures designed
to harmonize (i) the various management systems of the acquired companies and
(ii) the management styles of management personnel of the acquired companies.
There can be no assurance that significant problems in these areas will not
occur. Any failure to continue to expand or replace, as applicable, these
systems and implement such procedures and controls in an efficient manner and
at a pace consistent with the Company's business could have a material adverse
effect on the Company's business, financial condition and results of
operations.
In connection with the Company's acquisitions and growth, the Company's
operating expenses have increased significantly, and the Company anticipates
that operating expenses will continue to increase in absolute dollars in the
future. In particular, in order to continue to provide quality products and
customer service and to meet anticipated demands of its customers, the Company
will be required to continue to increase staffing and other expenses, including
expenditures on sales and marketing and the infrastructure to support them.
Should the Company increase its expenditures in anticipation of a future level
of sales that does not materialize, the Company's business, financial condition
and results of operations would be materially and adversely affected. Certain
customers have required and may continue to require rapid increases in
production and accelerated delivery schedules which have placed and may
continue to place a significant burden on the Company's resources. In order to
achieve anticipated sales levels and profitability, the Company will continue
to be required to manage its assets and operations efficiently. In addition,
should the Company continue to expand geographically, it may experience certain
inefficiencies from the management of geographically dispersed personnel and
other resources.
Although many of the companies acquired by the Company had significant
operating histories, the Company has limited experience owning and operating
them on a consolidated basis. Operational risks associated with an acquisition
include the possibility that an acquisition does not ultimately provide the
benefits originally anticipated by the Company's management, while the Company
continues to incur operating expenses to provide the services formerly provided
by the acquired company. Financial risks involve the incurrence of indebtedness
as a result of the acquisition and the consequent need to service that
indebtedness. In connection with an acquisition made in December 1996, the
Company paid an aggregate of $400,000 in cash. In addition, pursuant to the
exemption from registration provided for in Section 4(2) of the Securities Act,
the Company has issued approximately 2.8 million shares of Common Stock, which
represents approximately 38% of its outstanding and issued shares of Common
Stock at June 30, 1998, in connection with its six acquisitions since February
1996. The issuance of Common Stock dilutes the voting power and may dilute the
economic interests of existing stockholders. As part of the Company's growth
strategy, the Company
-7-
<PAGE> 9
will continue to review acquisition opportunities in the future, and in making
acquisitions, if any, the Company may issued additional shares of Common Stock,
other equity securities, debt securities or equity or debt securities
convertible into shares of Common Stock. In carrying out its acquisition
strategy, the Company attempts to minimize the risk of unexpected liabilities
and contingencies associated with acquired businesses through planning,
investigation and negotiation, but there is no assurance that it will be
successful in doing so. There can be no assurance that recent or future
acquisitions can be readily assimilated into the Company's operating structure.
Inability to efficiently integrate acquired companies could have a material
adverse effect on the Company's financial condition and results of operations.
The Company does not currently have any commitments or agreements with respect
to any material acquisitions.
MANAGEMENT OF GROWTH. The rapid growth of the Company's business has
required the Company to make significant additions in personnel and has
significantly increased the Company's working capital requirements. Although
the Company has experienced significant sales growth in 1996 and 1997, such
growth should not be considered indicative of future sales growth. Such growth
has resulted in new and increased responsibilities for management personnel and
has placed and continues to place a significant strain upon the Company's
management, operating and financial systems, and other resources. There can be
no assurance that the strain placed upon the Company's management, operating
and financial systems, and other resources will not have a material adverse
effect on the Company's business, financial condition, and results of
operations, nor can there be any assurance that the Company will be able to
attract or retain sufficient personnel to continue the expansion of its
operations. Also crucial to the Company's success in managing its growth will
be its ability to achieve additional economies of scale. There can be no
assurance that the Company will be able to achieve such economies of scale, and
the failure to do so could have a material adverse effect on the Company's
business, financial condition, and results of operations.
To manage the expansion of its operations, the Company must
continuously evaluate the adequacy of its management structure and its existing
systems and procedures, including, among others, its data processing,
financial, and internal control systems. When entering new geographic markets,
the Company will be required, on a timely and cost-effective basis, to hire
personnel, establish suitable distribution centers, and adapt the Company's
distribution systems and procedures to these new markets. There can be no
assurance that management will adequately anticipate all of the changing
demands that growth could impose on the Company's systems, procedures, and
structure. In addition, the Company will be required to react to changes in the
MIS distribution industry, and there can be no assurance that it will be able
to do so successfully. Any failure to adequately anticipate and respond to such
changing demands may have a material adverse effect on the Company's business,
financial condition, or results of operations.
EFFECTS OF DELISTING FROM NASDAQ SMALLCAP MARKET; LACK OF LIQUIDITY OF
LOW PRICED STOCKS. If the Company fails to maintain the qualification for its
Common Stock to trade on the Nasdaq SmallCap Market, its securities could be
subject to delisting. The Nasdaq Stock Market recently announced increases in
the quantitative standards for maintenance of listings on The Nasdaq SmallCap
Market. The revised standards for continued listing, which became effective in
February 1998, include maintenance of any of (x) $2,000,000 of net tangible
assets, (y) $35,000,000 of market capitalization or (z) $500,000 of net income
for two of the last three years and a minimum bid price per share of $1.00.
Although the Company is currently in compliance with the new Nasdaq SmallCap
Market continued listing requirements, no assurances can be given that the
Company will be able to maintain such compliance in the future. In the event
the Company is unable to satisfy the continued listing requirements, trading,
if any, in the Common Stock would thereafter be conducted in the
over-the-counter markets in the so-called "pink sheets" or the National
Association of Securities Dealer's "Electronic Bulletin Board." Consequently,
the liquidity of the Company's Common Stock would likely be impaired, not only
in the number of shares which could be bought and sold, but also through delays
in the timing of the transactions, reduction in security analysts' and the news
media's coverage, if any, of the Company and lower prices for the Company's
securities than might otherwise prevail.
In addition, if the Common Stock were to become delisted from trading
on the Nasdaq SmallCap Market and the trading price of the Common Stock were
below $5.00 per share, trading in the Common Stock would also be subject to the
requirements of certain rules promulgated under the Exchange Act, which require
additional disclosures by broker-dealers in connection with any trades
involving a stock defined as a penny stock (generally, any non-Nasdaq equity
security that has a market price of less than $5.00 per share, subject to
certain exceptions). Such rules require the delivery, prior to any penny stock
transaction, of a disclosure schedule explaining the penny stock market and the
risks associated therewith, and impose various sales practice requirements on
broker-dealers who sell penny stock to
-8-
<PAGE> 10
persons other than established customers and accredited investors (which are
generally institutions). For these types of transactions, the broker-dealer
must make a special suitability determination for the purchase and have
received the purchaser's written consent to the transaction prior to the sale.
The additional burdens imposed upon broker-dealers by such requirements may
discourage broker-dealers from effecting transactions in the Common Stock which
could severely limit the market liquidity of Common Stock and the ability of
purchasers in this offering to sell their shares of Common Stock in the
secondary market.
PRODUCTS SUPPLY: DEPENDENCE ON KEY SUPPLIERS. The ability of the
Company to obtain particular products or product lines in the required
quantities to fulfill customer orders for MIS devices on a timely basis is
critical to the Company's success. In most cases, the Company has no guaranteed
price or delivery agreements with its MIS device suppliers. As a result, the
Company may experience short-term inventory shortages. In addition,
manufacturers of MIS devices who currently distribute their products through
the Company may decide to distribute, or to substantially increase their
existing distribution through other distributors, their own dealer networks, or
directly to resellers. The Company's primary supplier, Origin MedSystems, Inc.,
provided products which accounted for 38% of the Company's revenues in 1997 and
42% of the Company's revenues through June 30, 1998. The Company is a party to
a distribution agreement with such supplier which terminates in May 1999. There
can be no assurance that the Company will be able to renew the distribution
agreement with its primary supplier and the failure to do so will have an
adverse impact on the Company's business, financial condition and results of
operations. There can be no assurance that the Company's suppliers will be able
to maintain an adequate supply of products to fulfill the Company's customer
orders on a timely basis or that the Company will be able to obtain particular
products or that a product line currently offered by suppliers will continue to
be available. Failure of the Company to obtain particular products or product
lines in the required quantities or to fulfill customer orders on a timely
basis could have a material adverse effect on its business, financial condition
or results of operation.
The Company's ability to achieve increases in net sales or to sustain
current net sales levels depends in part on the ability and willingness of the
Company's suppliers to provide products in the quantities the Company requires.
Although the Company has written distribution agreements with many of its
suppliers, these agreements in certain instances provide for non-exclusive
distribution rights and often include territorial restrictions that limit the
geographical area in which the Company is permitted to distribute the products.
The agreements are also generally short-term, subject to periodic renewal and
often contain provisions permitting termination by either party without cause
upon relatively short notice. The termination of an agreement may have a
material adverse effect on the Company's business, financial condition or
result of operations.
RELIANCE ON FUTURE PRODUCTS AND NEW APPLICATIONS; UNCERTAINTY OF
TECHNOLOGY CHANGES. The markets for the Company's products are characterized by
rapid, unpredictable and significant technological change. Competition in the
Company's industry is intense. Many of the Company's competitors have greater
financial resources, research and development capabilities and more experience
in obtaining regulatory approvals, manufacturing and marketing than the
Company. Accordingly, these competitors may succeed in developing, obtaining
regulatory approval for and some have commercialized their products more
rapidly than the Company. The Company has significantly decreased its research
and development expenditures, and intends to acquire the majority of its new
products for distribution through distribution agreements with various
manufacturers. There can be no assurance that developments by the Company's
competitors or potential competitors will not render the Company's MIS products
noncompetitive, uneconomical or obsolete. There can be no assurance that the
Company will be able to successfully obtain new MIS products or technologies,
manufacture products in commercial volumes or gain market acceptance of its
products or the products of others. Delays in development, manufacturing or
market acceptance of new or enhanced products could have a material adverse
effect on the Company's business, financial condition and results of
operations. The future success of the Company will also depend upon, among
other factors, its ability to obtain and distribute new and enhanced versions
of products in a timely fashion.
INTENSE COMPETITION. The primary industry in which the Company
competes, minimally invasive surgery, is dominated by two large,
well-positioned entities that are intensely competitive and frequently offer
substantial discounts as a competitive tactic. The United States Surgical
Corporation ("U.S. Surgical") is primarily engaged in developing, manufacturing
and marketing surgical wound management products, and has historically been the
firm most responsible for providing products that have led to the growth of the
industry. U.S. Surgical supplies a broad line of products to the MIS industry,
including products which facilitate access, assessment and treatment. Ethicon
Endo-
-9-
<PAGE> 11
Surgery ("Ethicon"), a Johnson & Johnson company, has made a major investment
in the MIS field in recent years and is one of the leading suppliers
of hospital products in the world. Furthermore, U.S. Surgical and Ethicon each
utilize purchasing contracts that link discounts on the purchase of one product
to purchases of other products in their broad product lines. Substantially all
of the hospitals in the United States have purchasing contracts with one or
both of these entities. Accordingly, customers may be dissuaded from purchasing
access products from the Company rather than U.S. Surgical or Ethicon to the
extent it would cause them to lose discounts on products that they regularly
purchase from U.S. Surgical or Ethicon.
The Company faces a formidable task in successfully gaining and
maintaining significant revenues within the MIS access market. In order to
succeed, management believes that the Company will need to objectively
demonstrate substantial product benefits, and its sales effort must be able to
effectively present such benefits to both clinicians and health care
administrators. The MIS access market is dominated by U.S. Surgical and
Ethicon. A number of other entities participate in various segments of the MIS
access market.
There can be no assurance that the Company will be able to successfully
compete in the MIS access market, and failure to do so would have a material
adverse effect on the Company's business, financial condition and results of
operations.
RISK RELATED TO INTANGIBLE ASSETS. Largely as a result of acquisitions,
goodwill accounts for approximately 17% and 37% of the Company's total assets
and stockholders' equity, respectively, at June 30, 1998. Goodwill was
approximately $1.8 million at June 30, 1998. Goodwill arises when an acquirer
pays more for a business than the fair value of the tangible and separately
measurable intangible net assets acquired. The Company periodically evaluates
whether events and circumstances have occurred indicating that any portion of
the remaining balance of amounts allocable to the Company's intangible assets
may not be recoverable. If factors indicate that the carrying value of the
Company's intangible assets has been impaired, the Company would be required to
reduce the carrying value of such assets. Any future determination requiring
the write-off of a significant portion of the unamortized intangible assets
could have a material adverse effect on the Company's business, results of
operations or financial condition. A reduction in net income resulting from the
amortization of goodwill may have an adverse impact upon the market price of
the Company's Common Stock.
OWNERSHIP BY MANAGEMENT AND PRINCIPAL STOCKHOLDERS. At August 15, 1998,
certain principal stockholders and directors and officers of the Company
beneficially owned (as defined by Rule 13d-3 promulgated under the Securities
Exchange Act of 1934, as amended) in the aggregate approximately 3,854,275
shares of Common Stock, representing approximately 41% of the shares of Common
Stock which would be outstanding in the event such directors and officers
exercised their stock options and converted their shares of Series A Preferred
Stock, as applicable, and such stockholders converted their Debentures and
shares of Series A Preferred Stock. In addition, at August 15, 1998 certain
principal stockholders and directors and officers of the Company held 1,610,375
shares of the Company's Common Stock, representing approximately 22.3% of the
issued and outstanding shares of Common Stock of the Company. Accordingly, such
stockholders, directors and officers have the ability to influence
significantly the affairs of the Company and matters requiring a stockholder
vote, including the election of the Company's directors, the amendment of the
Company's charter documents, the merger or dissolution of the Company and the
sale of all or substantially all of the Company's assets. The voting power of
these stockholders may also discourage or prevent any proposed takeover of the
Company pursuant to a tender offer.
DEPENDENCE UPON INDEPENDENT SHIPPING COMPANIES. The Company relies
heavily on arrangements with independent shipping companies for the delivery of
its products. In order to meet customer demand, products are shipped from
suppliers through independent shipping companies. Currently, the Company's
management estimates that United Parcel Service ("UPS") delivers approximately
90% of the Company's products to its customers. The termination of the
Company's relationship with UPS, or the failure of one or more other
independent shipping companies to deliver products from suppliers to the
Company or products from the Company to its customers could have a material
adverse effect on the Company's business, financial condition or results of
operations. For instance, another employee work stoppage at UPS or an employee
work stoppage or slow-down at one or more of these independent shipping
companies could materially impair the shipping company's ability to perform the
services required by the Company. There can be no assurance that the services
of these independent shipping companies will
-10-
<PAGE> 12
continue to be available to the Company on terms as favorable as those
currently available or that these companies will choose or be able to perform
the required shipping services for the Company.
HEALTH CARE MARKET; UNCERTAINTY RELATED TO THIRD-PARTY REIMBURSEMENT.
The health care industry continues to undergo change, led primarily by market
forces which are demanding greater efficiencies and reduced costs. Government
proposed health care mandates in the United States have not occurred, and it is
unclear whether, and to what extent, any government mandate will affect the
domestic health care market. Industry led changes are expected to continue
irrespective of any governmental efforts toward health care reform. The scope
and timing of any further government sponsored proposals for health care reform
are presently unclear.
The primary trend in the industry is toward consolidation and cost
containment. Third-party payors, principally federal Medicare, state Medicaid
and private health insurance plans, have been able to exercise greater
influence through managed treatment and hospitalization patterns, including a
shift from reimbursement on a cost basis to per capita limits for patient
treatment. Hospitals have been severely impacted by the resulting cost
restraints. The increasing use of managed care, centralized purchasing
decisions through group purchasing organizations, consolidations among
hospitals and hospital groups, and integration of health care providers are
continuing to affect purchasing patterns in the health care system. Purchasing
decisions are often shared by a coalition of surgeons, nursing staff, and
hospital administrators, with purchasing decisions taking into account whether
a product reduces the cost of treatment and/or attracts additional patients to
a hospital. Managed care providers are attempting to control the cost of health
care by authorizing fewer elective surgical procedures. All of these factors
have contributed to reductions in prices for the Company's products, to a
reduction in the volume of hospital purchasing and, in the near term, slower
acceptance of more advanced surgical procedures in which the Company's products
are used, given hospital and surgeon concerns as to the costs of training and
reimbursement by payors. While the Company has implemented programs to assist
hospitals in cost containment through more efficient surgical practices and
application of minimally invasive surgery, there can be no assurance that the
Company will not continue to be adversely affected by these matters. There can
be no assurance as to the impact of cost containment on the Company's future
operations.
The Company's products are purchased by hospitals, physicians, and
other health care providers, which in turn bill various third-party payors,
such as government health programs, private health insurance plans, managed
care organizations and other similar programs, for the health care goods and
services provided to their patients. Third-party payors may deny reimbursement
if they determine that a product was not used in accordance with established
payor protocol regarding cost-effective treatment methods, or was used for an
unapproved treatment. Increasingly, third-party payors are also contesting the
prices charged for medical products and services and, in some instances, have
put pressure on medical device suppliers to lower their prices. There is no
assurance that reimbursement for procedures performed by healthcare providers
utilizing the Company's products will be available or, if available, that the
third-party payors' reimbursement levels will not adversely affect the
Company's ability to sell its products on a profitable basis. Failure by
hospitals and other users of the Company's products to obtain reimbursement
from third-party payors, and changes in third-party payors' policies towards
reimbursement for procedures utilizing the Company's products, could have a
material adverse effect on the Company's financial position, results of
operations and cash flows.
GOVERNMENT REGULATION. As a manufacturer of medical devices, the
Company is subject to regulation by, among other governmental entities, the
Food and Drug Administration (the "FDA") and the corresponding agencies of
states and foreign countries in which the Company sells its products. These
regulations govern the introduction of new medical devices, the observance of
certain standards with respect to the manufacture and labeling of such devices,
the maintenance of certain records and the reporting of potential product
defects and other matters. Failure to comply with such regulations may have a
material adverse effect on the Company.
With the enactment of the Medical Device Amendments in May 1976 to the
Federal Food, Drug and Cosmetic Act (the "FDC Act"), the FDA classified medical
devices in commercial distribution into three classes, Class I, II or III. This
classification is based on the controls necessary to reasonably ensure the
safety and effectiveness of the medical device. Class I devices are those
devices whose safety and effectiveness can reasonably be ensured through
general controls such as adequate labeling, premarket notification and
adherence to GMP regulations. Some Class I devices are further exempted from
some of the general controls. Class II devices are those devices whose safety
and effectiveness can reasonably be ensured through the use of special controls
such as performance standards, post-market surveillance, patient registries and
FDA guidelines. Class III devices are devices which must receive premarket
-11-
<PAGE> 13
approval by the FDA pursuant to a Premarket Approval ("PMA") application to
ensure their safety and effectiveness. Generally, Class III devices are limited
to life-sustaining, life-supporting or implantable devices.
Most medical instruments introduced to the United States market are
required by the FDA, as a condition of marketing, to secure either clearance of
a premarket notification pursuant to Section 510(k) of the FDC Act (a "510(k)
Notification") or an approved PMA. Obtaining PMA can take several years. In
contrast, the process of obtaining a 510(k) Notification clearance requires the
submission of substantially less data and generally involves a shorter review
period.
In general, clearance of a 510(k) Notification may be obtained if a
manufacturer or distributor of medical devices can establish that a new device
is "substantially equivalent" to a legally marketed medical device. The 510(k)
Notification and the claim of substantial equivalence may have to be supported
by various types of information indicating that the device is as safe and
effective for its intended use as a legally marketed predicate device. In
addition to requiring clearance for new products, FDA rules typically require a
filing and a waiting period prior to marketing modified versions of existing
products. The Company anticipates that most of its products will be eligible
for the 510(k) Notification procedure. At this time, the FDA typically responds
to a submission of a 510(k) Notification within 180 to 360 days. Market
clearance may take three to 12 months or longer. In the event that the shorter
510(k) Notification procedure is not available, the Company will be required to
file a PMA.
Under the Safe Medical Devices Act of 1990 ("SMDA"), the FDA is
directed to adopt new 510(k) Notification regulations which could potentially
make the approval process for the Company's products more time-consuming,
difficult and expensive. The SMDA includes new provisions relating to
post-market surveillance requirements for certain types of devices and
authorizes the FDA to adopt new controls to be applied to certain devices such
as some currently being developed by the Company, including the promulgation of
a performance standard, requirements for patient registries, distributor and
purchaser reporting and imposition of guidelines.
The process of obtaining necessary government approvals can be
time-consuming and expensive. There can be no assurance that the necessary
approvals will be obtained by the Company or, if they are obtained, that they
will be obtained on a timely basis. Furthermore, the Company or the FDA may
suspend clinical trials at any time upon a determination that the subjects or
patients are being exposed to an unacceptable health risk. The FDA may also
require post-approval testing and surveillance programs to monitor the effects
of the Company's products and the products it distributes as a condition of
approval. Approvals that have been or may be granted are subject to continual
review and surveillance programs required by regulatory agencies, and later
discovery of previously unknown problems may result in product labeling
restrictions or withdrawal of products from marketing.
Manufacturers of medical devices marketed in the United States are
required to adhere to applicable regulations setting forth detailed Good
Manufacturing Practices ("GMP") requirements, which include testing, control
and documentation requirements. Manufacturers also must comply with Medical
Device Reporting ("MDR") requirements which require that a firm report to the
FDA certain adverse events associated with the Company's devices. The Company
is subject to routine inspection by the FDA and certain state agencies for
compliance with GMP requirements, MDR requirements and other applicable
regulations. The FDA is using its statutory authority more vigorously during
inspections of companies and in other enforcement matters. The FDA has
promulgated new GMP regulations and MDR regulations, both of which will likely
increase the cost of compliance with GMP requirements. The Company also is
subject to numerous federal, state and local laws relating to matters such as
safe working conditions, manufacturing practices, environmental protection,
fire hazard control and disposal of hazardous or potentially hazardous
substances. Changes in existing requirements or adoption of new requirements
could have a material adverse effect on the Company's business, financial
condition or results of operations. Although the Company believes that it is in
compliance with all applicable regulations of the FDA and the various states in
which it operates, current regulations depend heavily on administrative
interpretation and there can be no assurance that the Company will not incur
significant costs to comply with laws and regulations in the future or that
laws and regulations will not have a material adverse effect upon the Company's
business, financial condition or results of operations. In addition, the
potential effects on the Company of heightened enforcement of federal and state
regulations cannot be predicted.
All of the products manufactured by the Company have received all
regulatory approvals as required, and the Company believes , to its best
knowledge, that all of the products it distributes but does not manufacture
have received
-12-
<PAGE> 14
all regulatory approvals as required. The Company has no applications for
approval before either the FDA or any similar regulatory body in other
countries nor does the Company anticipate filing any applications in the near
future. The Company has never had any sales in Europe nor has it ever applied
for the CE mark for sales in Europe. In addition, the Company has no plans to
conduct any operations in Europe.
In addition to the statutes and regulations enforced by the FDA, the
Company is also subject to regulation under the Occupational Safety and Health
Act, the Environmental Protection Act, the Toxic Substances Control Act, the
Resource Conservation and Recovery Act and other present and potential future
federal, state and local statutes, regulations and ordinances, including those
promulgated by the Environmental Protection Act and the Department of Labor.
Regulations regarding the manufacture and sale of the Company's products are
subject to change. The Company cannot predict what impact, if any, such changes
might have on its business.
DEPENDENCE ON KEY PERSONNEL. The success of the Company will be largely
dependent on the efforts of a number of key management and technical personnel,
including Richard A. Woodfield, President and Chief Executive Officer of the
Company and Randall K. Boatright, Executive Vice-President, Chief Financial
Officer and Secretary of the Company. The Company has entered into employment
agreements with each of Mr. Woodfield and Mr. Boatright. The Company does not
maintain key man life insurance on either Mr. Boatright or Mr. Woodfield. The
loss of the services of one or more key employees could have an adverse effect
on the Company. The Company believes that its future success will depend in
large part upon its ability to hire and retain suitable operating, marketing,
financial and technical personnel. The competition for qualified personnel in
the medical device industry is intense and, accordingly, there can be no
assurance that the Company will be able to hire or retain necessary personnel.
PRODUCT LIABILITY: CLAIMS IN EXCESS OF INSURANCE COVERAGE. The
development, manufacture and sale of MIS products by the Company entails the
risk of product liability claims, involving both potential financial exposure
and associated adverse publicity. The Company's current product liability
insurance coverage limits are $1,000,000 per occurrence and $2,000,000 in the
aggregate, and there can be no assurance that such coverage limits are adequate
to protect the Company from any liabilities it might incur in connection with
the development, manufacture and sale of its current and potential products. In
addition, the insurance is expensive and may not be available in the future on
acceptable terms, or at all. In addition, if such insurance is available, there
can be no assurance that the limits of coverage of such policies will be
adequate. A successful product liability claim in excess of the Company's
insurance coverage could have a material adverse effect on the Company's
business, financial condition or results of operations.
STOCK PRICE VOLATILITY. The stock market in general, and stocks of
medical device companies in particular, have from time to time experienced
significant price and volume fluctuations that are unrelated to the operating
performance of particular companies. These broad market fluctuations may
adversely affect the market price of the Company's Common Stock. In addition,
the market price of the Common Stock has been and is likely to continue to be
highly volatile. Factors such as fluctuations in the Company's operating
results, announcements of technological innovations or new products by the
Company or its competitors, the FDA and international regulatory actions,
actions with respect to reimbursement matters, developments with respect to
patents of proprietary rights, public concern as to the safety of products
developed or marketed by the Company or others, changes in health care policy
in the United States and internationally, changes in stock market analyst
recommendations regarding the Company, or the medical device industry generally
or general market conditions may have a significant effect on the market price
of the Company's Common Stock.
SHARES ELIGIBLE FOR FUTURE SALE OR ISSUANCE. Sales of shares of Common
Stock by existing stockholders under Rule 144 of the Securities Act, or through
the exercise of outstanding vested options or the conversion of the Debentures
or Series A Preferred Stock, could have an adverse effect on the price of the
Common Stock. On the date of this Prospectus, in addition to the 370,000 shares
of Common Stock offered hereby, approximately 870,000 shares of Common Stock
held by affiliates of the Company are eligible for sale in the public market
upon compliance with the volume and other limitations contained in Rule 144 of
the Securities Act. In addition, on the date of this Prospectus, there were
outstanding options to acquire up to approximately 437,000 shares of Common
Stock under the Company's stock option plan, options to acquire up to
approximately 762,000 additional shares of Common Stock under option agreements
entered into outside of such plan, 1,500,000 shares of Common Stock issuable
upon conversion of the Debentures and 585,000 shares of Common Stock issuable
upon conversion of Series A Preferred
-13-
<PAGE> 15
Stock. In the event a large number of shares are sold in the public market over
a short period of time, the market price for Common Stock could decline.
LIMITED MANUFACTURING EXPERIENCE. The Company initiated manufacture of
commercial quantities of MIS devices in 1997 and maintains limited
manufacturing facilities. Accordingly, the Company has limited experience in
manufacturing MIS access products in commercial quantities at acceptable costs.
The Company's success will depend in part on its ability to manufacture its
products in compliance with the FDA's Good Manufacturing Practices ("GMP")
regulations and other regulatory requirements in sufficient quantities and on a
timely basis, while maintaining product quality and acceptable manufacturing
costs. Manufacturers often encounter difficulties in scaling up production of
new products, including problems involving production yields, technological
problems, quality control and assurance, component supply and shortages of
qualified personnel. Failure to maintain satisfactory regulatory system
compliance could have a significant impact on the Company's ability to continue
to manufacture and distribute its products and, in the most serious cases,
result in the seizure or recall of products. Failure to maintain production
volumes or increase production volumes in a timely or cost-effective manner
would have a material adverse effect on the Company's business, financial
condition and results of operations. In the event that the Company is unable to
efficiently operate its manufacturing facilities, the Company will be required
to enter into arrangements with others for the manufacture and packaging of the
products it currently manufactures. There can be no assurance that the Company
will be able to enter into any such arrangements on commercially reasonable
terms, or at all, or that the Company will ever manufacture all of its products
on a commercial basis. See - "Government Regulation."
RIGHTS AGREEMENT. On June 21, 1995, the Board of Directors of the
Company declared a dividend of one Common Stock purchase right (a "Right") for
each share of Common Stock outstanding. Each Right entitles the holder to
purchase one share of the Company's Common Stock at an initial exercise price
of $7.00 per share, subject to adjustment, upon the terms and subject to the
conditions set forth in a Rights Agreement dated as of June 20, 1995, between
the Company and American Stock Transfer & Trust Company, as the Rights Agent.
The Rights trade with the Common Stock and will not detach from the Common
Stock or become exercisable until the earlier of (i) ten business days after a
public announcement that a person or group of affiliated or associate persons
("Acquiring Person") has acquired beneficial ownership of 15% or more of the
Company's Common Stock (a "Shares Acquisition Date") and (ii) ten business days
after the commencement of, or the first public announcement of an intention to
make, a tender offer or exchange offer for the Common Stock, the consummation
of which would result in beneficial ownership by a person or group.
If any person or group acquires beneficial ownership of 15% or more of
the outstanding shares of the Company's Common Stock, each Right (other than
the Rights held by the Acquiring Person, which shall be void), will entitle its
holder to purchase at the exercise price an additional number of shares of
Common Stock equal to the amount determined by dividing the exercise price by
50% of the then current market price of the Common Stock.
In addition, if following the Shares Acquisition Date, the Company is
acquired in a merger or other business-combination transaction, or sells more
than 50% of its assets or earning power to any person, each Right (other than
those beneficially held by an Acquiring Person) will entitle its holder to
purchase at the existing exercise price a number of shares of common stock of
the acquiring company having twice the value of the exercise price.
The Company may redeem the Rights at $.02 per Right at any time on or
prior to the tenth business day following the first public announcement of the
acquisition by a person of 15% or more of its Common Stock or the commencement
of a tender offer or exchange offer for such 15% ownership.
The Rights have certain anti-takeover effects. The Rights will cause
substantial dilution to a person or group who attempts to acquire the Company
without conditioning the offer on a substantial number of Rights being
acquired. The Rights may also deter a person or group from attempting to
acquire the Company and therefore may inhibit the ability of stockholders of
the Company to sell their shares of Common Stock at a premium price in a
takeover situation. The Rights should not interfere with any merger or other
business combination approved by the Board of Directors of the Company since
the Board of Directors may, at its option, at any time prior to the close of
business on the tenth business day after the Shares Acquisition Date, redeem
all the then outstanding Rights at a price of $.02 per Right.
-14-
<PAGE> 16
CERTAIN ANTI-TAKEOVER EFFECTS OF PROVISIONS OF THE CERTIFICATE OF
INCORPORATION AND DELAWARE LAW. Certain provisions of the Delaware General
Corporation Law ("DGCL") and the Company's Certificate of Incorporation could
have the effect of making it more difficult for a third party to acquire, or of
discouraging a third party from acquiring, control of the Company. Such
provisions could limit the price that certain investors might be willing to pay
in the future for shares of Common Stock. These provisions of the DGCL and
provisions of the Company's Certificate of Incorporation may also have the
effect of discouraging or preventing certain types of transactions involving an
actual or threatened change of control of the Company (including unsolicited
takeover attempts), even though such a transaction may offer the Company's
stockholders the opportunity to sell their stock at a price above the
prevailing market price. The Company is subject to the provisions of Section
203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware
corporation from engaging in a "business combination" with an "interested
stockholder" for a period of three years after the date that the person became
an interested stockholder unless (with certain exceptions) the business
combination or the transaction in which the person became an interested
stockholder is approved in a prescribed manner. Generally, a "business
combination" includes a merger, asset or stock sale, or other transaction
resulting in a financial benefit to the stockholder. Generally, an "interested
stockholder" is a person who, together with affiliates and associates, owns (or
within three years prior to such transaction, did own) 15% or more of the
corporation's voting stock.
The Company's Certificate of Incorporation authorizes the issuance of
preferred stock with designations, rights and preferences determined from time
to time by its Board of Directors. The Board of Directors may issue one or more
series of preferred stock, without any action on the part of the stockholders
of the Company, the terms of which may adversely affect the rights of holders
of Common Stock. Issuance of preferred stock, which may be accomplished through
a public offering or a private placement, may dilute the voting power of
holders of Common Stock (such as by issuing preferred stock with super voting
rights) and may render more difficult the removal of current management, even
if such removal may be in the stockholders' best interests.
The issuance of preferred stock, for example, could decrease the amount
of earnings or assets available for distribution to the holders of Common Stock
or could adversely affect the rights and powers, including voting rights, of
the holders of Common Stock. In certain circumstances, such issuance could have
the effect of decreasing the market price of the Common Stock, as well as
having the anti-takeover effect discussed above. Further, the issuance of
preferred stock may be used as an "anti-takeover" device without further action
on the part of the stockholders. Although the Company issued 1,170 shares of
preferred stock in August 1998, it has no present intention to issue any
additional shares of its preferred stock, however, there can be no assurance
that it will not do so in the future.
NONPAYMENT OF DIVIDENDS. The Company has never declared or paid
dividends on Common Stock and does not anticipate paying dividends on Common
Stock at any time in the foreseeable future. The terms of the Company's
convertible debentures and loan agreements restrict the payment of dividends on
Common Stock.
-15-
<PAGE> 17
GLOSSARY OF TECHNICAL TERMS
autoclave an apparatus for effecting sterilization by steam under
pressure; it is fitted with a gauge that automatically
regulates the pressure, and therefore the degree of
heat to which the contents are subjected.
cannula a tube for insertion into a duct or cavity; during
insertion its lumen is usually occupied by a trocar.
electrocautery an apparatus for cauterizing tissue, consisting of a
platinum wire in a holder which is heated to a red or
white heat when the instrument is activated by an
electric current.
endoscope an instrument for the examination of the interior of a
hollow viscus, such as the bladder.
laparoscope an instrument comparable to an endoscope which, when
inserted into the peritoneal cavity, permits it to be
inspected; peritoneoscope.
laparoscopy examination of the interior of the abdomen by means of
a laparoscope.
peperitoneal situated between the parietal peritoneum and the
abdominal wall, or occurring anterior to the peritoneum.
peritoneum the serous membrane lining the abdominopelvic walls and
investing the viscera. A strong, colorless membrane
with a smooth surface, it forms a double-layered sac
that is closed in the male and it continuous with the
mucous membrane of the uterine tubes in the female. The
potential space between the parietal and visceral
peritoneum is called the peritoneal cavity.
pneumopreperitoneum the presence of air or gas in the preperitoneal space;
it may occur spontaneously or be deliberately
introduced as an aid to radiologic examination and
diagnosis.
retractor an instrument for maintaining operative exposure by
separating the edges of a wound and holding back
underlying organs and tissues; many shapes, sizes, and
styles are available; any retractile muscle.
stapling the act or process of closing a wound fastening with
staples instead of sutures.
trocar a sharp-pointed instrument equipped with a cannula,
used to puncture the wall of a body cavity and withdraw
fluids.
-16-
<PAGE> 18
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
This Prospectus contains certain "forward-looking statements" within
the meaning of Section 27A of the Securities Act and Section 21E of the
Exchange Act. Specifically, all statements other than statements of historical
facts included in this report regarding the Company's financial position,
business strategy and plans and objectives of management of the Company for
future operations are forward-looking statements. These forward-looking
statements are based on the beliefs of the Company's management, as well as
assumptions made by and information currently available to the Company's
management. When used in this report, the words "anticipate," "believe,"
"estimate," "expect" and "intend" and words or phrases of similar import, as
they relate to the Company or Company management are intended to identify
forward-looking statements. Such statements reflect the current view of the
Company with respect to future events and are subject to certain risks,
uncertainties and assumptions related to certain factors including, without
limitation, competitive factors, general economic conditions, customer
relations, relationships with vendors, the interest rate environment,
governmental regulation and supervision, product introductions and acceptance,
technological change, changes in industry practices, one-time events and other
factors described herein ("cautionary statements"). Although the Company
believes that its expectations are reasonable, it can give no assurance that
such expectations will prove to be correct. Based upon changing conditions,
should any one or more of these risks or uncertainties materialize, or should
any underlying assumptions prove incorrect, actual results may vary materially
from those described herein as anticipated, believed, estimated, expected or
intended. All subsequent written and oral forward-looking statements
attributable to the Company or persons acting on its behalf are expressly
qualified in their entirety by the applicable cautionary statements.
-17-
<PAGE> 19
USE OF PROCEEDS
The Shares to be sold pursuant to the Prospectus are owned by a
stockholder (the "Selling Stockholder") of the Company. The Company will not
receive any of the proceeds from the sale of the Shares. See "Selling
Stockholder."
SELLING STOCKHOLDERS
The following table sets forth the name of the Selling Stockholder and,
as of June 30, 1998, the beneficial ownership of Common Stock held by the
Selling Stockholder, immediately prior to and upon completion of this offering.
All information as to beneficial ownership has been furnished by the Selling
Stockholder. The number of Shares that may be actually sold by the Selling
Stockholder will be determined by the Selling Stockholder, and may depend upon
a number of factors, including, among other things, the market price of the
Common Stock. Because the Selling Stockholder may offer all, some or none of
the Shares that it holds, and because the offering contemplated by this
Prospectus is currently not being underwritten, no estimate can be given as to
the number of Shares that will be held by the Selling Stockholder upon or prior
to the termination of this offering. See "Plan of Distribution." Except as
otherwise specified, the Selling Stockholder has sole voting and investment
power over the shares listed. Except as set forth below, the Selling
Stockholder has not had a material relationship with the Company or any of its
predecessors or affiliates within the past three years.
<TABLE>
<CAPTION>
BENEFICIAL OWNERSHIP BENEFICIAL OWNERSHIP
BEFORE THE OFFERING AFTER THE OFFERING(1)
NUMBER PERCENTAGE SHARES TO NUMBER PERCENTAGE
NAME OF SHARES OF CLASS(2) BE SOLD OF SHARES OF CLASS(2)
---- ----------- ----------- --------- ------------ -----------
<S> <C> <C> <C> <C> <C>
ANA-Tech, L.L.C.(3) 370,000 5.13% 370,000 0 0
=====================================================================================================
</TABLE>
* Represents less than 1%
(1) Assumes all shares of Common Stock offered hereby are sold. (2) Based on
7,212,742 shares of Common Stock outstanding as of June 30, 1998.
(3) Represents shares issued pursuant to a Subscription Agreement between
such stockholder and the Company dated June 9, 1998
In June 1998, the Company issued 370,000 shares of Common Stock to
Ana-Tech, L.L.C. in exchange for approximately 4% of the ownership interests of
Ana-Tech, L.L.C. Ana-Tech, L.L.C. is a developmental stage company engaged in
the development, manufacturing and distribution of fecal incontinence devices.
-18-
<PAGE> 20
PLAN OF DISTRIBUTION
The Company is registering the Shares on behalf of the Selling
Stockholder. All costs, expenses and fees in connection with the registration
of the Shares offered hereby will be borne by the Company. Brokerage
commissions, if any, attributable to the sale of Shares will be borne by the
Selling Stockholder (or its donees or pledgees).
The Shares may be sold from time to time by or for the account of the
Selling Stockholder in the over-the-counter market, on the Nasdaq SmallCap
Market or otherwise at prices and on terms then prevailing or at prices related
to the then current market price, or in negotiated transactions. The Shares may
be sold by any one or more of the following methods: (a) a block trade in which
the broker or dealer so engaged will attempt to sell the securities as agent
but may position and resell a portion of the block as principal to facilitate
the transaction; (b) purchases by a broker or dealer as principal and resale by
such broker or dealer for its account pursuant to this Prospectus; (c) ordinary
brokerage transactions and transactions in which the broker solicits
purchasers; and (d) privately negotiated transactions. The Selling Stockholder
will act independently of the Company in making decisions with respect to the
timing, manner and size of each sale. To the Company's knowledge, the Selling
Stockholder has not entered into any agreements, understandings or arrangements
with any underwriters or broker-dealers regarding the sale of the Shares, nor
does the Company know the identity of the brokers or market makers which will
participate in the offering. The Selling Stockholder may effect such
transactions by selling the Shares directly to purchasers or to or through
broker-dealers which may act as agents or principals. In effecting sales,
broker-dealers engaged by the Selling Stockholder may arrange for other
broker-dealers to participate. Such broker-dealers may receive compensation in
the form of discounts, concessions or commissions from the Selling Stockholder
and/or the purchasers of Common Stock for whom such broker-dealers may act as
agents or to whom they sell as principal, or both (which compensation as to a
particular broker-dealer might be in excess of customary commissions). The
Selling Stockholder and any broker-dealers that act in connection with the sale
of the Shares might be deemed to be "underwriters" within the meaning of
Section 2(11) of the Securities Act and any commission received by them and any
profit on the resale of the shares of Common Stock as principal might be deemed
to be underwriting discounts and commissions under the Securities Act. The
Selling Stockholder may agree to indemnify any agent, dealer or broker-dealer
that participates in transactions involving sales of the shares against certain
liabilities, including liabilities arising under the Securities Act.
Liabilities under the federal securities laws cannot be waived. Because the
Selling Stockholder may be deemed to be an "underwriter" within the meaning of
Section 2(11) of the Securities Act, the Selling Stockholder will be subject to
prospectus delivery requirements under the Securities Act. Furthermore, the
Selling Stockholder, any broker or dealer and any "affiliated purchasers" will
be subject to the applicable provisions of the Exchange Act and the Securities
Act and the rules and regulations thereunder, including, without limitation,
Regulation M under the Exchange Act, which provisions may limit the timing of
the purchases and sales of the Company's securities by the Selling Stockholder,
any broker or dealer and any "affiliated purchasers."
The Company will receive no portion of the proceeds of the sale of the
Shares offered hereby and will bear all costs and expenses incident to their
registration.
LEGAL MATTERS
The validity of the securities offered hereby will be passed upon for
the Company by Fulbright & Jaworski L.L.P., San Antonio, Texas.
EXPERTS
The consolidated financial statements included in the Company's Annual
Report on Form 10-KSB for the fiscal year ended December 31, 1997 incorporated
by reference in this Prospectus have been audited by Arthur Andersen LLP,
independent public accountants, to the extent and for the periods set forth in
their reports incorporated herein by reference, and are incorporated herein in
reliance upon the authority of said firm as experts in giving said reports.
-19-
<PAGE> 21
<TABLE>
<S> <C>
=========================================== ===========================================
NO DEALER, SALESMAN OR OTHER PERSON HAS BEEN
AUTHORIZED TO GIVE ANY INFORMATION OR TO
MAKE ANY REPRESENTATIONS NOT CONTAINED IN 370,000 SHARES
THIS PROSPECTUS, AND, IF GIVEN OR MADE,
SUCH INFORMATION OR REPRESENTATIONS MUST NOT
BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY THE COMPANY. THIS PROSPECTUS DOES NOT
CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION
OF AN OFFER TO BUY, THE SECURITIES OFFERED LIFEQUEST MEDICAL, INC.
HEREBY IN ANY JURISDICTION TO ANY PERSON TO
WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR
SOLICITATION IN SUCH JURISDICTION. THE
DELIVERY OF THIS PROSPECTUS AT ANY TIME DOES
NOT IMPLY THAT THE INFORMATION CONTAINED
HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT COMMON STOCK
TO ITS DATE.
-----------------------------
TABLE OF CONTENTS ----------
PAGE
Available Information............. 2
Incorporation of Certain Documents 2 P R O S P E C T U S
The Company....................... 3
Risk Factors...................... 4
Glossary of Technical Terms........ 16 OCTOBER 2, 1998
Disclosure Regarding Forward-Looking
Statements................. 17
Use of Proceeds.................... 18
Selling Stockholders............... 18 ----------
Plan of Distribution............... 19
Legal Matters..................... 19
Experts........................... 19
=========================================== ===========================================
</TABLE>
<PAGE> 22
PART II
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The estimated expenses in connection with this offering are:
SEC registration fee* $ 266
Legal fees and expenses* 10,000
Miscellaneous* 1,000
------
Total* $ 11,266
--------------------
* Estimated
The Company has agreed to pay all the costs and expenses of this
offering.
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 145 of the Delaware General Corporation Law empowers the
Registrant to, and the Bylaws of the Registrant provide that it shall,
indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding by reason of
the fact that he is or was a director, officer, employee or agent of the
Registrant, or is or was serving at the request of the Registrant as a
director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses, judgments, fines and
amounts paid in settlement actually and reasonably incurred by him in
connection with such action, suit or proceeding if he acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interest
of the Registrant, and, with respect to any criminal action or proceeding, had
no reasonable cause to believe his conduct was unlawful; except that, in the
case of an action or suit by or in the right of the Registrant, no
indemnification may be made in respect of any claim, issue or matter as to
which such person shall have been adjudged to be liable for negligence or
misconduct in the performance of his duty to the Registrant unless and only to
the extent that the Court of Chancery or the court in which such action or suit
was brought shall determine that such person is fairly and reasonably entitled
to indemnity for proper expenses.
ITEM 16. EXHIBITS.
Exhibit No. Exhibit
- ----------- -------
5 Opinion of Fulbright & Jaworski L.L.P. regarding legality.
23.1 Consent of Fulbright & Jaworski L.L.P. (contained in Exhibit 5).
23.2 Consent of Arthur Andersen LLP.
24 Power of Attorney (included on signature page).
ITEM 17. UNDERTAKINGS.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement to include any
material information with respect to the plan of distribution not previously
disclosed in the registration statement or any material change to such
information in the registration statement;
II-1
<PAGE> 23
(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination
of the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 that is incorporated by reference in the registration
statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
(c) The undersigned registrant hereby undertakes that, insofar as
indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
II-2
<PAGE> 24
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets
all the requirements for filing on Form S-3 and has duly caused this
registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of San Antonio and State of Texas the 30th day of
September, 1998.
LIFEQUEST MEDICAL, INC.
By: /s/ Randall K. Boatright
-------------------------------
Randall K. Boatright
Executive Vice President, Chief
Financial Officer and Secretary
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each individual whose signature
appears below constitutes and appoints Richard A. Woodfield or Randall K.
Boatright, or either of them, his true and lawful attorney-in-fact and agent,
with full power of substitution and resubstitution, for him and in his name,
place and stead, in any and all capacities, to sign any and all amendments
(including post-effective amendments) to this Registration Statement, and to
file the same and all exhibits thereto, and all documents in connection
therewith, with the Securities and Exchange Commission, granting said
attorney-in-fact and agent, and each of them, full power and authority to do
and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that said
attorney-in-fact and agent or either of them, or their or his substitute or
substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- --------- ----- ----
<S> <C> <C>
/s/ Richard A. Woodfield** September 30, 1998
- -----------------------------
Richard A. Woodfield President, Chief Executive
Officer and Director
(Principal Executive Officer)
/s/ Randall K. Boatright Executive Vice President, September 30, 1998
- ----------------------------- Chief Financial Officer and Director
Randall K. Boatright (Principal Financial Officer,
and Principal Accounting Officer)
/s/ William H. Bookwalter** September 30, 1998
- -----------------------------
William H. Bookwalter Vice President and Director
/s/ Kalford C. Fadem** September 30, 1998
- -----------------------------
Kalford C. Fadem Vice President and Director
/s/ Richard H. Klein**
- -----------------------------
Richard H. Klein Vice President and Director
/s/ Robert B. Johnson** September 30, 1998
- -----------------------------
Robert B. Johnson Vice President and Director
</TABLE>
II-3
<PAGE> 25
<TABLE>
<S> <C> <C>
s/ Jeffrey H. Berg** September 30, 1998
- -----------------------------
Jeffrey H. Berg Director
/s/ Robert L. Evans** September 30, 1998
- -----------------------------
Robert L. Evans Director
</TABLE>
** By: /s/ Randall K. Boatright
---------------------------
Randall K. Boatright
Attorney-in-Fact
II-4
<PAGE> 26
EXHIBIT INDEX
EXHIBIT NO.
- ----------
5 Opinion of Fulbright & Jaworski L.L.P. regarding legality
23.1 Consent of Fulbright & Jaworski L.L.P. (contained in Exhibit 5)
23.2 Consent of Arthur Andersen LLP
24 Power of Attorney (included on signature page)
<PAGE> 1
EXHIBIT 5
[FULBRIGHT & JAWORSKI LETTERHEAD]
July 1, 1998
LifeQuest Medical, Inc.
12961 Park Central, Suite 1300
San Antonio, Texas 78216
Dear Sirs:
We refer to the Registration Statement on Form S-3 (the "Registration
Statement") to be filed on or about July 1, 1998, by LifeQuest Medical, Inc.
(the "Company") under the Securities Act of 1933, as amended, relating to an
aggregate of 370,000 shares of Common Stock, $.001 par value ("Common Stock"),
to be sold by a certain selling stockholder listed in the Registration Statement
(the "Selling Stockholder").
As counsel for the Company, we have examined such corporate records,
documents and such questions of law as we have considered necessary or
appropriate for the purposes of this opinion and, upon the basis of such
examination, advise you that in our opinion the 370,000 shares of Common Stock
to be sold by the Selling Stockholder have been duly and validly authorized,
have been legally issued, and are fully paid and nonassessable.
We consent to the filing of this opinion as an exhibit to the
Registration Statement and the reference to this firm under the caption "Legal
Matters" in the prospectus contained therein and elsewhere in the Registration
Statement and prospectus. This consent is not to be construed as an admission
that we are a party whose consent is required to be filed with the Registration
Statement under the provisions of the Securities Act of 1933, as amended.
Very truly yours,
/s/ Fulbright & Jaworski L.L.P.
<PAGE> 1
EXHIBIT 23.2
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation by
reference in this registration statement of our report dated March 16, 1998
included in LifeQuest Medical, Inc.'s Form 10-KSB for the year ended December
31, 1997 and to all references to our Firm included in this registration
statement.
/s/ ARTHUR ANDERSEN LLP
San Antonio, Texas
September 29, 1998
